Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Research & Development (2016 - 2025)

PAVmed has reported Research & Development over the past 5 years, most recently at $1.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 126.52% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $4.5 million, down 43.72%, while the annual FY2025 figure was $4.5 million, 24.28% down from the prior year.
  • Research & Development for Q4 2025 was $1.8 million at PAVmed, up from $1.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $7.0 million in Q4 2021 and troughed at $787000.0 in Q1 2025.
  • A 5-year average of $3.6 million and a median of $3.5 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 77.55% in 2024 and later soared 126.52% in 2025.
  • Year by year, Research & Development stood at $7.0 million in 2021, then dropped by 4.23% to $6.7 million in 2022, then plummeted by 46.13% to $3.6 million in 2023, then tumbled by 77.55% to $807000.0 in 2024, then soared by 126.52% to $1.8 million in 2025.
  • Business Quant data shows Research & Development for PAVM at $1.8 million in Q4 2025, $1.1 million in Q3 2025, and $790000.0 in Q2 2025.